Table_1_Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers.DOCX

Healthcare workers were prioritized in vaccination campaigns globally because they are exposed to the highest risk of contamination by SARS-CoV-2. This study evaluated the self-reported post-vaccination side effects of inactivated (BBIBP-CorV and CoronaVac) and adenoviral vector-based (AZD1222, Gam-COVID-Vac and Ad26.COV2.S) vaccines among Algerian healthcare workers using a validated questionnaire. The final analysis included 721 healthcare workers, with a predominance of females (59.1%) and younger individuals 20–30 years old (39.4%). Less than half (49.1%) of the respondents reported at least one local side effect, while 53.8% reported at least one systemic side effect. These side effects were more prevalent among viral vector vaccinees than inactivated virus vaccinees. The most common local side effects were injection site pain (39%) and arm pain (25.4%), while fatigue (34.4%), fever (28.4%), headache (24.8%) and myalgia (22.7%) were the most prevalent systemic side effects. The side effects appeared earlier among inactivated virus vaccines recipients and generally lasted for 2 to 3 days for the two vaccinated groups. The risk factors associated with a higher prevalence of side effects included female gender, allergic individuals, individuals with regular medication, those who contracted the COVID-19 disease and those who received two doses for both inactivated and viral-based vaccines groups. Despite the higher prevalence of post-vaccination side effects among adenoviral vector vaccines recipients, both vaccines groups were equally effective in preventing symptomatic infections, and no life-threatening side effects were reported in either vaccine group.

全球新冠疫苗接种活动均将医护人员列为优先接种人群，因其面临最高的新冠病毒（SARS-CoV-2）暴露感染风险。本研究通过经验证的问卷，对阿尔及利亚医护人员接种两类疫苗后的自我报告接种后不良反应展开评估：一类为灭活疫苗（inactivated vaccine，BBIBP-CorV与CoronaVac），另一类为腺病毒载体疫苗（adenoviral vector-based vaccine，AZD1222、Gam-COVID-Vac及Ad26.COV2.S）。最终纳入本研究分析的医护人员共721名，其中女性占比59.1%，20~30岁的年轻群体占比39.4%，为受试人群的主体。仅有不到半数（49.1%）的受访者报告出现至少1种局部不良反应，而报告至少1种全身不良反应的受访者占比达53.8%。腺病毒载体疫苗接种者的不良反应发生率显著高于灭活疫苗接种者。最常见的局部不良反应为注射部位疼痛（39%）与手臂疼痛（25.4%）；全身不良反应中发生率最高的依次为乏力（34.4%）、发热（28.4%）、头痛（24.8%）及肌痛（22.7%）。灭活疫苗接种者的不良反应出现时间更早，且两类疫苗接种者的不良反应持续时间普遍为2~3天。与不良反应发生率升高相关的危险因素包括女性、过敏体质者、长期规律服药者、既往感染新冠病毒者，以及灭活疫苗与腺病毒载体疫苗组中完成两剂接种的人群。尽管腺病毒载体疫苗接种者的不良反应发生率更高，但两类疫苗在预防有症状感染方面的防护效果相当，且两组均未报告危及生命的严重不良反应。